Google
Trusted Resources: News & Events
Latest announcements and gatherings
Public Meeting on Patient-Focused Drug Development for Chronic Pain
Meeting Information:
On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain.
Date: July 9, 2018
Time: 10:00 a.m. – 4:00 p.m. (registration will begin at 9:00am)
Location:
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
This event has ended.
+myBinderRelated Content
-
“Pain Is Subjective”: A Mixed-Method Study of Provider Attitudes and Practices Regarding Pain Management in Sick...Sickle cell disease (SCD), an autosomal ...
-
Sickle Cell Disease Virtual Forum: Historically Black Colleges and Universities 16-Day ChallengeYou’re invited to the Sickle Cell Dise...
-
Treatment options for sickle cell disease – chronic blood transfusionsBlood transfusions are scheduled and giv...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
-
In A 1st, Doctors In U.S. Use CRISPR Tool To Treat Patient With Genetic DisorderFor the first time, doctors in the U.S. ...
-
In France, Boy Becomes First Sickle Cell Disease Patient to be Treated With Gene TherapyA 13-year-old boy with sickle cell disea...
-
What is a Bone Marrow Transplant?https://www.youtube.com/watch?v=wrfT5wqH...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.